3-Phenyl-6-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazolo[1,5-a]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Phenyl-6-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazolo[1,5-a]pyrimidine
• 化学式: C₂₆H₂₈N₄
• 分子量: 396.5
• InChiKey: ALSLXIDTHGPFNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  33.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Tyrosine kinase inhibitors
  申请人：Fraley E. Mark

  公开号：US20060183755A1

  公开（公告）日：2006-08-17

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号传导的化合物，包含这些化合物的组合物，以及使用它们治疗哺乳动物的酪氨酸激酶依赖性疾病和病状的方法，例如血管生成、癌症、肿瘤生长、动脉硬化、年龄相关性黄斑变性、糖尿病性视网膜病变、黄斑水肿、视网膜缺血、炎症性疾病等。
• US7262199B2
  申请人：——

  公开号：US7262199B2

  公开（公告）日：2007-08-28
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2004052286A2

  公开（公告）日：2004-06-24

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.
• [EN] METHODS OF TREATING LYMPHOPENIA<br/>[FR] MÉTHODES DE TRAITEMENT DE LA LYMPHOPÉNIE
  申请人：[en]KEROS THERAPEUTICS, INC.

  公开号：WO2022098821A1

  公开（公告）日：2022-05-12

  The invention features methods of treating or preventing lymphopenia in a subject treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by co-administering an iron supplement with the inhibitor, and methods of treating a subject who has or is at risk of developing a disease or condition that can be treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by administering to the subject a BMP inhibitor or a hepcidin inhibitor and an iron supplement.